EDWARDS LIFESCIENCES CORP (EW) Stock Price, Forecast & Analysis

NYSE:EW • US28176E1082

82.12 USD
-0.32 (-0.39%)
Last: Feb 24, 2026, 01:27 PM

EW Key Statistics, Chart & Performance

Key Statistics
Market Cap47.65B
Revenue(TTM)6.07B
Net Income(TTM)1.37B
Shares580.30M
Float573.17M
52 Week High87.89
52 Week Low65.94
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)2.56
PE32.08
Fwd PE27.62
Earnings (Next)04-21
IPO2000-03-27
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
EW short term performance overview.The bars show the price performance of EW in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 2 -2 4 -4 6 8

EW long term performance overview.The bars show the price performance of EW in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 5 10 15

The current stock price of EW is 82.12 USD. In the past month the price decreased by -1.46%. In the past year, price increased by 15.11%.

EDWARDS LIFESCIENCES CORP / EW Daily stock chart

EW Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to EW. When comparing the yearly performance of all stocks, EW turns out to be only a medium performer in the overall market: it outperformed 54.7% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
EW Full Technical Analysis Report

EW Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to EW. EW has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
EW Full Fundamental Analysis Report

EW Financial Highlights

Over the last trailing twelve months EW reported a non-GAAP Earnings per Share(EPS) of 2.56. The EPS decreased by -2.29% compared to the year before.


Industry RankSector Rank
PM (TTM) 23.25%
ROA 10.31%
ROE 13.4%
Debt/Equity 0.06
Chartmill High Growth Momentum
EPS Q2Q%-1.69%
Sales Q2Q%13.26%
EPS 1Y (TTM)-2.29%
Revenue 1Y (TTM)10.86%
EW financials

EW Forecast & Estimates

43 analysts have analysed EW and the average price target is 98.01 USD. This implies a price increase of 19.35% is expected in the next year compared to the current price of 82.12.

For the next year, analysts expect an EPS growth of 16.14% and a revenue growth 10.47% for EW


Analysts
Analysts79.53
Price Target98.01 (19.35%)
EPS Next Y16.14%
Revenue Next Year10.47%
EW Analyst EstimatesEW Analyst Ratings

EW Ownership

Ownership
Inst Owners89.94%
Ins Owners0.11%
Short Float %1.41%
Short Ratio2.09
EW Ownership

EW Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABT ABBOTT LABORATORIES19.85200.474B
ISRG INTUITIVE SURGICAL INC48.39174.759B
SYK STRYKER CORP25.25147.128B
BSX BOSTON SCIENTIFIC CORP21.45110.292B
BDX BECTON DICKINSON AND CO11.6652.52B
IDXX IDEXX LABORATORIES INC43.6249.757B
GEHC GE HEALTHCARE TECHNOLOGY16.8138.219B
RMD RESMED INC20.5837.992B
DXCM DEXCOM INC28.9828.573B

About EW

Company Profile

EW logo image Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California. The company went IPO on 2000-03-27. The firm partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. The company is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.

Company Info

EDWARDS LIFESCIENCES CORP

One Edwards Way

Irvine CALIFORNIA 92614 US

CEO: Michael A. Mussallem

Employees: 15800

EW Company Website

EW Investor Relations

Phone: 13026587581

EDWARDS LIFESCIENCES CORP / EW FAQ

What does EW do?

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California. The company went IPO on 2000-03-27. The firm partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. The company is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.


What is the current price of EW stock?

The current stock price of EW is 82.12 USD. The price decreased by -0.39% in the last trading session.


Does EDWARDS LIFESCIENCES CORP pay dividends?

EW does not pay a dividend.


How is the ChartMill rating for EDWARDS LIFESCIENCES CORP?

EW has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


How is the valuation of EDWARDS LIFESCIENCES CORP (EW) based on its PE ratio?

The PE ratio for EDWARDS LIFESCIENCES CORP (EW) is 32.08. This is based on the reported non-GAAP earnings per share of 2.56 and the current share price of 82.12 USD.


What is the Short Interest ratio of EDWARDS LIFESCIENCES CORP (EW) stock?

The outstanding short interest for EDWARDS LIFESCIENCES CORP (EW) is 1.41% of its float.